Nippon India Pharma Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended) Factsheet
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return Index
NAV: ₹630.36-1.13%
17 Jul 2026
Loading…
Expense ratio of the scheme (1.0%) is lower than average expense ratio of the category (1.64%), excluding index funds and ETFs
This measures the relative expense of the scheme with respect to average expense ratio of the category. Investors should always prefer schemes with lower expense, everything else remaining the same
What is Expense ratio?
The scheme has marginally underperformed its benchmark (BSE Healthcare Total Return Index) with an alpha of -0.73% in the last 3 years
This measures the risk-adjusted outperformance of the scheme with respect to the benchmark calculated based on last 3 years of performance. Higher alpha implies higher outperformance (in the last 3 years)
What is Alpha (3Y)?
3-year CAGR of 20.81% is between 25th and 75th percentile in its category - Equity: Sectoral-Pharma
This is measured by percentile rank of the scheme in its category based on 3-year CAGR. Lower rank implies that scheme was a relative outperformer in its category
What is CAGR (3Y)?
The scheme was a top-quartile (25%) performer in 5.0 out of last 12 quarters
This is measured as the number of quarters, in the last 12 quarters, that the scheme was in the top quartile (25th percentile). Higher number implies that scheme has been a consistent performer
What is Consistency (quarterly)?
Volatility of scheme returns is roughly in the range of average volatility of the category
This measures the volatility of monthly returns of the scheme (in the last 3 years) with respect to average volatility of the category. Higher number implies that scheme has been riskier that average category risk
What is Volatility (3Y)?
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.